Abnormalities of calcium–phosphate balance, with subsequent bone metabolism disorders, are among the key and earliest features of chronic kidney disease (CKD). Recently, another consequence of these abnormalities was brought to light—namely, vascular calcification. Most studies performed in patients on dialysis suggest that their vascular calcification is more advanced than that seen in the general population. Furthermore, the progression of vessel wall mineralization is much more dynamic in patients with CKD.
Apart from the commonly assessed factors that promote vascular calcification, such as age, duration of dialysis, or poor control of calcium–phosphate status, several other factors have recently been identified. In the spectrum of substances involved in the regulation of the process of soft-tissue calcification, the most extensively studied in the nephrology literature are bone morphogenetic protein 7, osteoprotegerin, matrix Gla protein, fetuin-A, and the phosphatonins. Better understanding of the mechanisms underlying excess vascular mineralization have led to the development of promising new therapies.
BlockGAKlassenPSLazarusJMOfsthunNLowrieEGChertowGM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol2004; 15:2208–18.
2.
BraunJOldendorfMMoshageWHeidlerRZeitlerELuftFC. Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. Am J Kidney Dis1996; 27:394–401.
3.
GoodmanWGGoldinJKuizonBDYoonCGalesBSiderD. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med2000; 342:1478–83.
4.
RaggiPBoulayAChasan–TaberSAminNDillonMBurkeSK. Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease?J Am Coll Cardiol2002; 39:695–701.
5.
MerjanianRBudoffMAdlerSBermanNMehrotraR.Coronary artery, aortic wall, and valvular calcification in nondialyzed individuals with type 2 diabetes and renal disease. Kidney Int2003; 64:263–71.
6.
MoeSMO'NeillKDFinebergNPersohnSAhmedSGarrettPMeyerCA. Assessment of vascular calcification in ESRD patients using spiral CT. Nephrol Dial Transplant2003; 18:1152–8.
7.
StomporTPasowiczMSullowiczWDembinska–KiecAJandaKWojcikK. An association between coronary artery calcification score, lipid profile, and selected markers of chronic inflammation in ESRD patients treated with peritoneal dialysis. Am J Kidney Dis2003; 41:203–11.
8.
SharplesEJPereiraDSummersSCunninghamJRubensMGoldsmithD. Coronary artery calcification measured with electron-beam computerized tomography correlates poorly with coronary artery angiography in dialysis patients. Am J Kidney Dis2004; 43:313–19.
9.
HaydarAACovicAColhounHRubensMGoldsmithDJA. Coronary artery calcification is related to coronary atherosclerosis in chronic renal disease patients: a study comparing EBCT-generated coronary artery calcium scores and coronary angiography. Nephrol Dial Transplant2004; 19: 2307–12.
10.
TamashiroMIsekiKSunagawaOInoueTHigaSAfusoH. Significant association between the progression of coronary artery calcification and dyslipidemia in patients on chronic hemodialysis. Am J Kidney Dis2001; 38: 64–9.
11.
ChertowGMBurkeSKRaggiP for the Treat to Goal Working Group. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int2002; 62:245–52.
12.
MoeSMO'NeillKDResterovaMFinebergNPersohnSMeyerCA. Natural history of vascular calcification in dialysis and transplant patients. Nephrol Dial Transplant2004; 19:2387–93.
13.
StomporTPPasowiczMSulowiczWDembinska–KiecAJandaKWojcikK. Trends and dynamics of changes in calcification score over the 1-year observation period in patients on peritoneal dialysis. Am J Kidney Dis2004; 44:517–28.
14.
StomporTPasowiczMSulowiczWDembinska-KiecATraczW.Trends in coronary artery calcification in peritoneal dialysis and transplant patients. Nephrol Dial Transplant2004; 19:3205–6.
15.
OhJWunschRTurzerMBahnerMRaggiPQuerfeldU. Advanced coronary and carotid arteriopathy in young adults with childhood-onset chronic renal failure. Circulation2002; 106:100–5.
16.
GuerinAPLondonGMMarchaisSJMetivierF.Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant2000; 15:1014–21.
17.
PanuccioVTripepiRTripepiGMallamaciFBenedettoFACataliottiA. Heart valve calcifications, survival, and cardiovascular risk in hemodialysis patients. Am J Kidney Dis2004; 43:479–84.
18.
LocatelliF.The need for better control of secondary hyperparathyroidism. Nephrol Dial Transplant2004; 19(Suppl 5):V15–19.
19.
LondonGMMartyCMarchaisSJGuerinAPMetivierFde VernejoulMC. Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol2004; 15:1943–51.
20.
WangAYLamCWWangMChanIHGaoPLuiSF. Associations of serum fetuin-A with malnutrition, inflammation, atherosclerosis and valvular calcification syndrome and outcome in peritoneal dialysis patients. Nephrol Dial Transplant2005; 20:1676–85.
21.
FloegeJ.When man turns to stone: extraosseous calcification in uremic patients. Kidney Int2004; 65:2447–62.
22.
GiachelliCMJonoSShioiANishizawaYMoriKMoriiH.Vascular calcification and inorganic phosphate. Am J Kidney Dis2001; 38(Suppl 1):S34–7.
23.
ShioiATaniwakiHJonoSOkunoYKoyamaHMoriK. Monckeberg's medial sclerosis and inorganic phosphate in uremia. Am J Kidney Dis2001; 38(Suppl 1):S47–9.
24.
TintutYPatelJParhamiFDemerLL. Tumor necrosis factor-alpha promotes in vitro calcification of vascular cells via the cAMP pathway. Circulation2000; 102:2636–42.
25.
ParhamiFTintutYBallardAFogelmanAMDemerLL. Leptin enhances the calcification of vascular cells: artery wall as a target for leptin. Circ Res2001; 88:954–60.
26.
ReselandJESyversenUBakkeIQvigstadGEideLGHjertnerO. Leptin is expressed in and secreted from primary cultures of human osteoblasts and promotes bone mineralization. J Bone Miner Res2001; 16:1426–33.
27.
MorrisseyJHruskaKGuoGWangSChenQKlahrS.Bone morphogenetic protein-7 improves renal fibrosis and accelerates the return of renal function. J Am Soc Nephrol2002; 13(Suppl 1):S14–21.
28.
DaviesMRLundRJHruskaKA. BMP-7 is an efficacious treatment of vascular calcification in a murine model of atherosclerosis and chronic renal failure. J Am Soc Nephrol2003; 14:1559–67.
29.
DaviesMRLundRJMatthewSHruskaKA. Low turnover osteodystrophy and vascular calcification are amenable to skeletal anabolism in an animal model of chronic kidney disease and the metabolic syndrome. J Am Soc Nephrol2005; 16:917–28.
30.
LiTSurendranKZawaidehMAMathewSHruskaKA. Bone morphogenetic protein 7: a novel treatment for chronic renal and bone disease. Curr Opin Nephrol Hypertens2004; 13:417–22.
31.
SchoppetMPreissnerKTHofbauerLC. RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function. Arterioscler Thromb Vasc Biol2002; 22:549–53.
32.
BucayNSarosiIDunstanCRMoronySTarpleyJCapparelliC. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev1998; 12:1260–8.
33.
PricePAJuneHHBuckleyJRWilliamsonMK. Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D. Arterioscler Thromb Vasc Biol2001; 21:1610–16.
34.
JonoSIkariYShioiAMoriKMikiTHaraK. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation2002; 106:1192–4.
35.
NittaKAkibaTUchidaKOtsuboSTakeiTYumuraW. Serum osteoprotegerin levels and the extent of vascular calcification in haemodialysis patients. Nephrol Dial Transplant2004; 19:1886–9.
36.
MoeSMReslerovaMKettelerMO'NeilKDuanDKoczmanJ. Role of calcification inhibitors in the pathogenesis of vascular calcification in chronic kidney disease (CKD). Kidney Int2005; 67:2295–304.
37.
CoenGBallantiPBalducciACalabriaSFischerMSJankovicL. Serum osteoprotegerin and renal osteodystrophy. Nephrol Dial Transplant2002; 17:233–8.
38.
HaasMLeko–MohrZRoschgerPKletzmayrJSchwartzCDomenigC. Osteoprotegerin and parathyroid hormone as markers of high-turnover osteodystrophy and decreased bone mineralization in hemodialysis patients. Am J Kidney Dis2002; 39:580–6.
39.
KazamaJJNaritaIGejyoFIwasakiYFukagawaM.Role of osteoprotegerin in the development of vascular calcification: does it have a protective function in situ? (Abstract). J Am Soc Nephrol2005; 16(Suppl):53A.
40.
MunroePBOlgunturkRDFrynsJPVan MaldergemLZiereisenFYukselB. Mutations in the gene encoding the human matrix Gla protein cause Keutel syndrome. Nat Genet1999; 21:142–4.
41.
SchaeferCHeissCSchwarzAWestenfeldRKettelerMFloegeJ. The serum protein α2–Heremans–Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest2003; 112:357–66.
42.
WangHZhangMSodaKSamaATraceyKJ. Fetuin protects the fetus from TNF. Lancet1997; 350:861–2.
43.
WangHZhangMBianchiMSherryBSamaATraceyKJ. Fetuin (α2-HS-glycoprotein) opsonizes cationic macrophage deactivating molecules. Proc Natl Acad Sci U S A1998; 95:14429–34.
44.
JersmannHPDransfieldIHartSP. Fetuin/α2-HS glycoprotein enhances phagocytosis of apoptotic cells and macropinocytosis by human macrophages. Clin Sci (Lond)2003; 105:273–8.
45.
StenvinkelPWangKQureshiARAxelssonJPecoits–FilhoRGaoP. Low fetuin-A levels are associated with cardiovascular death: impact of variations in the gene encoding fetuin. Kidney Int2005; 67:2383–92.
46.
KettelerMBongartzPWestenfeldRWildbergerJEMahnkenAHBohmR. Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet2003; 361:827–33.
47.
SchiaviSCKumarR.The phosphatonin pathway: new insights in phosphate homeostasis. Kidney Int2004; 65: 1–14.
48.
NakanishiSKazamaJNii–KonoTOmoriKYamashitaTFukumotoS. Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients. Kidney Int2005; 67:1171–8.
49.
KazamaJJSatoFOmoriKHamaHYamamotoSMaruyamaH. Pretreatment serum FGF-23 levels predict the efficacy of calcitriol therapy in dialysis patients. Kidney Int2005; 67:1120–5.
50.
RazzaqueMSSt-ArnaudMTaguchiTLanskeB.FGF-23, vitamin D and calcification: the unholy triad. Nephrol Dial Transplant2005; 20:2032–5.
51.
SukiWZabanehRCangianoJReedJFischerDSwanS. The DCOR Trial—a prospective, randomized trial assessing the impact on outcomes of sevelamer in dialysis patients. J Am Soc Nephrol2005; 16(Suppl):53A.
52.
FerramoscaEBurkeSChasan–TaberSRattiCChertowGMRaggiP.Potential antiatherogenic and anti-inflammatory properties of sevelamer in maintenance hemodialysis patients. Am Heart J2005; 149:820–5.
53.
CunninghamJDaneseMOlsonKKlassenPChertowGM. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int2005; 68:1793–800.
54.
TengMWolfMLowrieEOfsthunNLazarusJMThadhaniR.Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med2003; 349: 446–56.
55.
AchenbachSRopersDPohleKLeberAThiloCKnezA. Influence of lipid-lowering therapy on the progression of coronary artery calcification: a prospective evaluation. Circulation2002; 106:1077–82.
56.
BudoffMJYuDNasirKMehrotraRChenLTakasuJ. Diabetes and progression of coronary calcium under the influence of statin therapy. Am Heart J2005; 149: 695–700.
57.
AradYSpadaroLARothMNewsteinDGuerciAD. Treatment of asymptomatic adults with elevated coronary calcium scores with atorvastatin, vitamin C, and vitamin E: the St. Francis Heart Study randomized clinical trial. J Am Coll Cardiol2005; 46:166–72.
58.
RaggiPDavidsonMCallisterTQWaltyFKBachmanGAHechH. Aggressive versus moderate lipid-lowering therapy in hypercholesterolemic postmenopausal women: Beyond Endorsed Lipid Lowering with EBT Scanning (BELLES). Circulation2005; 112:563–71.
59.
WannerCKraneVMärzWOschewskiMMannJFRufG. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med2005; 353: 238–48.
60.
QuinibiWY. Dyslipidemia and progression of cardiovascular calcification (CVC) in patients with end-stage renal disease (ESRD). Kidney Int2005; 67(Suppl 95):S43–50.
61.
McClungMRLewieckiEMCohenSBBologneseMAWoodsonGCMoffetAH. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med2006; 354:821–31.
62.
BodyJJFaconTColemanRELiptonAGeursFFanM. A study of the biological receptor activator of nuclear factor-κB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res2006; 12:1221–8.
